This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News for CRMD
PBYI Surges 30% in 3 Months: How Should You Play the Stock?
CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?
CRMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain
JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal
Other News for CRMD
Directional Movement Crossover Bearish appears for CRMD after 2.24% move
Cormedix’s Positive Outlook: Buy Rating Backed by Strong Sales Guidance and Strategic Initiatives
CRMD forms NR7 on September 12
NR7 appears for CRMD after 2.35% move
20 Day Moving Average Resistance appears for CRMD after 1.84% move